M&A
confidence medium
sentiment positive
materiality 0.55
Catalyst announces CSRC approval for business combination with Beijing Continent
GYRE THERAPEUTICS, INC.
- Beijing Continent Pharmaceuticals received CSRC approval on Oct 20, 2023 for the business combination.
- Business Combination Agreement dated Dec 26, 2022, as amended, involves Catalyst and GNI entities.
- Parties anticipate completion by the outside date as defined in the agreement.
- Closing remains subject to satisfaction of other conditions.